Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Indira Brar

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Human Vaccines & Immunotherapeutics|April 28, 2023
Vaccine coverage and factors associated with vaccine adherence in persons with HIV at an urban infectious disease clinicNavina K Birk, Lea Monday, Tarandeep Singh, et al.
European Heart Journal. Case Reports|October 22, 2020
Cardiac sequelae of novel coronavirus disease 2019 (COVID-19): a clinical case seriesZachary D Demertzis, Carina Dagher, Kelly M Malette, et al.
Annals of Indian Academy of Neurology|April 23, 2019
Disseminated Strongyloidiasis: Breaking Brain BarriersIvy Anne Sebastian, Jeyaraj Durai Pandian, Aroma Oberoi, et al.
AIDS Research and Therapy|November 29, 2025
Effectiveness of B/F/TAF in adults with HIV who are viremic with M184V/ICharlotte-Paige Rolle, Michelle L D'Antoni, Roberto Corales, et al.
International Journal of STD & AIDS|September 15, 2025
A cross-sectional analysis of doxyPEP use and outcomes in Michigan, United StatesChristen J Arena, Nathan A Everson, Rachel M Kenney, et al.
Medicine|February 24, 2025
Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority studyIndira Brar, Peter J Ruane, Mezgebe Berhe, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 11, 2003
Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapyOmar Y Gonzalez, Daniel M Musher, Indira Brar, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 10, 2013
Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudyJennifer Hoy, Birgit Grund, Mollie Roediger, et al.
Open Forum Infectious Diseases|May 25, 2026
Renal Outcomes in People With HIV-1 and Renal Impairment Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide: Integrated Analysis From 9 Phase 3/3b Clinical TrialsFrank A Post, David Wohl, Geoffroy Liegeon, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 30, 2014
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 studyPaul E Sax, Andrew Zolopa, Indira Brar, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Human Vaccines & Immunotherapeutics|April 28, 2023
Vaccine coverage and factors associated with vaccine adherence in persons with HIV at an urban infectious disease clinicNavina K Birk, Lea Monday, Tarandeep Singh, et al.
European Heart Journal. Case Reports|October 22, 2020
Cardiac sequelae of novel coronavirus disease 2019 (COVID-19): a clinical case seriesZachary D Demertzis, Carina Dagher, Kelly M Malette, et al.
Annals of Indian Academy of Neurology|April 23, 2019
Disseminated Strongyloidiasis: Breaking Brain BarriersIvy Anne Sebastian, Jeyaraj Durai Pandian, Aroma Oberoi, et al.
AIDS Research and Therapy|November 29, 2025
Effectiveness of B/F/TAF in adults with HIV who are viremic with M184V/ICharlotte-Paige Rolle, Michelle L D'Antoni, Roberto Corales, et al.
International Journal of STD & AIDS|September 15, 2025
A cross-sectional analysis of doxyPEP use and outcomes in Michigan, United StatesChristen J Arena, Nathan A Everson, Rachel M Kenney, et al.
Medicine|February 24, 2025
Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority studyIndira Brar, Peter J Ruane, Mezgebe Berhe, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 11, 2003
Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapyOmar Y Gonzalez, Daniel M Musher, Indira Brar, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 10, 2013
Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudyJennifer Hoy, Birgit Grund, Mollie Roediger, et al.
Open Forum Infectious Diseases|May 25, 2026
Renal Outcomes in People With HIV-1 and Renal Impairment Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide: Integrated Analysis From 9 Phase 3/3b Clinical TrialsFrank A Post, David Wohl, Geoffroy Liegeon, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 30, 2014
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 studyPaul E Sax, Andrew Zolopa, Indira Brar, et al.
Pageof 5